iBio (IBIO) Competitors $0.68 -0.05 (-7.00%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.65 -0.03 (-3.69%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IBIO vs. ACRV, GRCE, EGRX, COEP, LVTX, SLGL, STTK, OVID, HYPD, and ENLVShould you be buying iBio stock or one of its competitors? The main competitors of iBio include Acrivon Therapeutics (ACRV), Grace Therapeutics (GRCE), Eagle Pharmaceuticals (EGRX), Coeptis Therapeutics (COEP), LAVA Therapeutics (LVTX), Sol-Gel Technologies (SLGL), Shattuck Labs (STTK), Ovid Therapeutics (OVID), Hyperion DeFi (HYPD), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. iBio vs. Its Competitors Acrivon Therapeutics Grace Therapeutics Eagle Pharmaceuticals Coeptis Therapeutics LAVA Therapeutics Sol-Gel Technologies Shattuck Labs Ovid Therapeutics Hyperion DeFi Enlivex Therapeutics iBio (NYSE:IBIO) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Is IBIO or ACRV more profitable? Acrivon Therapeutics' return on equity of -48.28% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets iBioN/A -73.15% -45.51% Acrivon Therapeutics N/A -48.28%-43.88% Does the media prefer IBIO or ACRV? In the previous week, Acrivon Therapeutics had 10 more articles in the media than iBio. MarketBeat recorded 10 mentions for Acrivon Therapeutics and 0 mentions for iBio. Acrivon Therapeutics' average media sentiment score of 0.39 beat iBio's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment iBio Neutral Acrivon Therapeutics Neutral Which has more volatility and risk, IBIO or ACRV? iBio has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Do insiders & institutionals hold more shares of IBIO or ACRV? 7.9% of iBio shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 0.6% of iBio shares are held by company insiders. Comparatively, 11.9% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings and valuation, IBIO or ACRV? iBio has higher revenue and earnings than Acrivon Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiBio$375K29.87-$24.91MN/AN/AAcrivon TherapeuticsN/AN/A-$80.56M-$2.25-0.62 Do analysts recommend IBIO or ACRV? iBio presently has a consensus target price of $5.00, suggesting a potential upside of 637.46%. Acrivon Therapeutics has a consensus target price of $17.57, suggesting a potential upside of 1,164.13%. Given Acrivon Therapeutics' higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than iBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryAcrivon Therapeutics beats iBio on 10 of the 12 factors compared between the two stocks. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$11.20M$791.77M$5.61B$21.04BDividend YieldN/A4.84%4.61%3.56%P/E RatioN/A1.1830.2728.02Price / Sales29.8726.06459.7557.05Price / CashN/A19.5638.2123.95Price / Book0.486.588.845.26Net Income-$24.91M-$4.98M$3.25B$994.11M7 Day Performance14.10%1.86%3.72%2.09%1 Month Performance-6.47%0.45%5.86%2.35%1 Year Performance-63.35%16.14%30.25%13.36% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio1.1988 of 5 stars$0.68-7.0%$5.00+637.5%-63.4%$11.20M$375K0.00100Gap UpACRVAcrivon Therapeutics2.986 of 5 stars$1.33+5.6%$17.71+1,231.9%-80.2%$41.70MN/A-0.6058News CoverageEarnings ReportAnalyst ForecastGap UpGRCEGrace Therapeutics2.8291 of 5 stars$3.00+4.5%$12.00+300.0%N/A$41.49MN/A-3.37N/APositive NewsEarnings ReportHigh Trading VolumeEGRXEagle PharmaceuticalsN/A$3.19-13.6%N/AN/A$41.43M$257.55M0.00100Gap DownCOEPCoeptis Therapeutics0.5018 of 5 stars$11.55+7.7%N/A+171.7%$40.54MN/A-1.992Earnings ReportShort Interest ↑LVTXLAVA Therapeutics1.9976 of 5 stars$1.47+3.5%$3.17+115.4%-13.0%$38.67M$4.99M-1.4160Earnings ReportUpcoming EarningsShort Interest ↓High Trading VolumeSLGLSol-Gel Technologies2.9586 of 5 stars$13.42+3.2%$40.00+198.1%+281.3%$37.44M$11.54M-2.8650Positive NewsSTTKShattuck Labs3.7586 of 5 stars$0.74+1.5%$7.50+909.8%-72.4%$35.58M$4.61M-0.53100News CoveragePositive NewsAnalyst ForecastOVIDOvid Therapeutics4.4382 of 5 stars$0.50-0.7%$3.13+529.4%-16.8%$35.31M$570K-1.4260Trending NewsEarnings ReportShort Interest ↑Gap DownHYPDHyperion DeFi0.3596 of 5 stars$6.29-11.2%$2.00-68.2%-89.1%$35.24M$67.06K-0.1140News CoverageEarnings ReportGap DownENLVEnlivex Therapeutics3.3568 of 5 stars$1.48+2.1%$10.00+575.7%+42.4%$35.00MN/A-2.2470News CoverageShort Interest ↓High Trading Volume Related Companies and Tools Related Companies ACRV Alternatives GRCE Alternatives EGRX Alternatives COEP Alternatives LVTX Alternatives SLGL Alternatives STTK Alternatives OVID Alternatives HYPD Alternatives ENLV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IBIO) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access